ArticleJournal of the Society for Cardiovascular Angiography & Interventions2026
Flow Gradients in Severe Aortic Stenosis and Preserved Ejection Fraction: A 10-Year Transcatheter Aortic Valve Replacement Study.
Article in Journal of the Society for Cardiovascular Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are limited and conflicting data on the long-term outcomes in normal-flow low-gradient (NFLG) and paradoxical low-flow low-gradient (pLFLG) aortic stenosis (AS) following transcatheter aortic valve replacement (TAVR). Methods: Patients who underwent TAVR for severe symptomatic native AS with preserved left ventricular ejection fraction (≥50%) from 2012 to 2022 at our center were included. The cohort was divided into 3 different hemodynamic AS groups: high-gradient aortic stenosis (HGAS) (aortic valve mean gradient [AVMG] ≥40 mm Hg, aortic valve [AV] peak velocity ≥4 m/s, and AV area ≤1 cm Results: Totally, 1683 patients (929 HGAS, 344 pLFLG, and 410 NFLG) were included; median age was 82.8 (77.2-87.2) years. At 1 year, mortality was higher among patients with pLFLG AS (15.5%) compared with HGAS (10.8%, Conclusions: In patients who undergo TAVR, those with a pLFLG pattern of AS have a worse 1-year survival, but similar 5-year survival when compared with traditional HGAS AS. There was no significant difference in survival in patients with NFLG AS when compared with HGAS at 1 and 5 years post-TAVR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.